Skip to main content
Top
Published in: Diabetologia 10/2007

01-10-2007 | Research Letter

Mutations in the SLC30A8 gene are not a major cause of MODY or other forms of early-onset, autosomal dominant type 2 diabetes

Authors: M. Borowiec, R. Thompson, C. Powers, R. Xu, T. Dickey, A. Doria

Published in: Diabetologia | Issue 10/2007

Login to get access

Excerpt

To the Editor: MODY is a relatively rare type of familial diabetes that is characterised by a young age of onset and an autosomal dominant mode of inheritance. The availability of large families with multiple affected members has facilitated genetic studies of this syndrome and this has led to the identification of six distinct MODY genes [1]. Several reports suggest that other MODY genes exist in addition to those identified to date [1, 2]. In the UK, about 15% of MODY cases do not seem to result from mutations in known MODY genes [2]. The proportion of unaccounted MODY is even higher if one uses a broader definition of the disease, one that takes into account the fact that MODY is often diagnosed after the traditional age limit of 25 years [1]. …
Literature
1.
go back to reference Doria A, Plengvidhya N (2000) Recent advances in the genetics of maturity onset diabetes of the young and other forms of autosomal dominant diabetes. Curr Opin Endocrinol Diabetes 7:203–210CrossRef Doria A, Plengvidhya N (2000) Recent advances in the genetics of maturity onset diabetes of the young and other forms of autosomal dominant diabetes. Curr Opin Endocrinol Diabetes 7:203–210CrossRef
2.
go back to reference Frayling TM, Evans JC, Bulman MP et al (2001) Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50(Suppl 1):S94–S100PubMedCrossRef Frayling TM, Evans JC, Bulman MP et al (2001) Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50(Suppl 1):S94–S100PubMedCrossRef
3.
go back to reference Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef
4.
go back to reference Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK. Samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK. Samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef
5.
go back to reference Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345PubMedCrossRef
6.
go back to reference Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef
7.
go back to reference Kim SH, Ma X, Weremowicz S et al (2004) Identification of a locus for maturity-onset diabetes of the young (MODY) on chromosome 8p23. Diabetes 53:1375–1380PubMedCrossRef Kim SH, Ma X, Weremowicz S et al (2004) Identification of a locus for maturity-onset diabetes of the young (MODY) on chromosome 8p23. Diabetes 53:1375–1380PubMedCrossRef
8.
go back to reference Frayling TM, Lindgren CM, Chevre JC et al (2003) A genome-wide scan in families with maturity-onset diabetes of the young: evidence for further genetic heterogeneity. Diabetes 52:872–881PubMedCrossRef Frayling TM, Lindgren CM, Chevre JC et al (2003) A genome-wide scan in families with maturity-onset diabetes of the young: evidence for further genetic heterogeneity. Diabetes 52:872–881PubMedCrossRef
9.
go back to reference Cauchi S, Vaxillaire M, Choquet H et al (2007) No major contribution of TCF7L2 sequence variants to maturity onset of diabetes of the young (MODY) or neonatal diabetes mellitus in French white subjects. Diabetologia 50:214–216PubMedCrossRef Cauchi S, Vaxillaire M, Choquet H et al (2007) No major contribution of TCF7L2 sequence variants to maturity onset of diabetes of the young (MODY) or neonatal diabetes mellitus in French white subjects. Diabetologia 50:214–216PubMedCrossRef
Metadata
Title
Mutations in the SLC30A8 gene are not a major cause of MODY or other forms of early-onset, autosomal dominant type 2 diabetes
Authors
M. Borowiec
R. Thompson
C. Powers
R. Xu
T. Dickey
A. Doria
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0777-y

Other articles of this Issue 10/2007

Diabetologia 10/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine